Genzyme GENZ

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. New operations chief at ImmunoGen

      Headlines

      Mon, 15 Sep 2014

      ImmunoGen ( IMGN -4% ) appoints Sandra E. Poole as SVP, Technical Operations reporting to CEO Daniel Junius. She joins the firm from Genzyme where she was SVP of biologics manufacturing. Post your comment!

    2. Positive interim results for Lemtrada

      Headlines

      Thu, 11 Sep 2014

      Genzyme (NYSE: SNY ) (NASDAQ: GCVRZ ) presents interim results from an extension study of Lemtrada ( alemtuzumab ) today at the European

    3. Genzyme looking for acquisitions to boost its position in MS

      Headlines

      Thu, 11 Sep 2014

      In an interview with Reuters , Genzyme 's (NYSE: SNY ) (NASDAQ: GCVRZ ) chief of its multiple sclerosis franchise Bill Sibold says his firm intends to be a leader

    4. Sanofi says MS drug Lemtrada shows sustained effect on disease

      Headlines

      Thu, 11 Sep 2014

      PARIS, Sept 11 (Reuters) - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.

    5. Sanofi aims to grow Genzyme unit with new drugs and acquisitions

      Headlines

      Thu, 11 Sep 2014

      PARIS, Sept 11 (Reuters) - Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through...

    6. New Morningstar Analyst Report for Sanofi

      Stock Reports

      Fri, 5 Sep 2014

      the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision

    7. FDA approves new drug for Gaucher's disease

      Headlines

      Tue, 19 Aug 2014

      The FDA clears Genzyme 's ( SNY -0.3% ) Cerdelga (eliglustat) an oral therapy for the ..... fatty materials by inhibiting the metabolic process that forms them. Genzyme 's first drug for Type 1 Gaucher disease was Ceredase ( alglucerase

    8. Second Quarter Results Confirm Why We Like Aastrom

      Headlines

      Tue, 19 Aug 2014

      recently acquired Cell Therapy and Regenerative Medicine (CTRM) business from Sanofi (NYSE: SNY ), previously known as Genzyme Biosurgery Aps. Total revenues for the quarter were approximately $4.4 million, and were comprised of approximately

    9. Aegerion Pharmaceuticals Is Still Significantly Overvalued

      Headlines

      Tue, 19 Aug 2014

      approximately one in a million people in the U.S., according to scientific studies, which made Juxtapid an orphan drug . Genzyme 's Kynamro, which has also been developed to treat HoFH, has also been granted an orphan drug status. Interestingly

    10. Sanofi Appears To Be In The Early Stages Of An Earnings Rebound

      Headlines

      Mon, 11 Aug 2014

      and substantially increased its presence in the lucrative biotechnology arena earlier this decade with the addition of Genzyme , is a diversified powerhouse, with a product portfolio that includes seven blockbusters and dozens of medicines/vaccines

    « Prev12345Next »
    Content Partners